15 recruiting, 8 completed, 5 active not recruiting, 4 not yet recruiting. 22 Phase 2, 10 Phase 1, 5 Not applicable, 3 Phase 3.
Follow HPV Positive Oropharyngeal Squamous Cell Carcinoma: new trials by email Literature Review of HPV Positive Oropharyngeal Squamous Cell Carcinoma trials Research Report on HPV Positive Oropharyngeal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs ATRN-119, Stereotactic Body Radiation Therapy (SBRT) - HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 35 | 2027-01-31 | 2026-10-27 |
| Prognostic Biomarkers for Patients With Human Papillomavirus (HPV) Positive Oropharyngeal Squamous Cell Carcinoma MRI - Oropharyngeal Squamous Cell Carcinoma (OPSCC), HPV | Not applicable | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 30 | 2026-09-15 | 2026-09-01 |
| A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED) Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease - Head and Neck Cancer, Head and Neck Squamous Cell Cancer | Phase 2 | Not yet recruiting | University of Maryland, Baltimore | 132 | 2026-09-01 | 2026-08-14 |
| Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma Cisplatin, Radiotherapy - Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sara Medek | 31 | 2026-05-13 | 2026-05-18 |
| CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs CUE-101, Pembrolizumab - Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | Yale University | 30 | 2026-05-07 | 2026-07-30 |
| A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. BVAC-E6E7 (low level), BVAC-E6E7 (high level), BVAC-E6E7 (RP2D) - Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma | Phase 1 / Phase 2 | Recruiting | Cellid Co., Ltd. | 37 | 2026-02-04 | 2026-07-08 |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-28 |
| A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) Sacituzumab Govitecan, Cetuximab - Squamous Cell Carcinoma of Head and Neck, Sinus Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2025-07-02 | 2026-02-19 |
| Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy - Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | Phase 3 | Terminated | PDS Biotechnology Corp. | 12 | 2025-05-30 | 2026-09-02 |
| De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE) De-escalation, Standard of care - HPV Positive Oropharyngeal Squamous Cell Carcinoma | Not applicable | Recruiting | Royal North Shore Hospital | 25 | 2025-04-01 | 2025-07-30 |
| Surgery and Reducing Ionizing Radiation of the Unknown Primary Intensity Modulated Radiotherapy (IMRT) to Mucosa at Risk, Surgical Intervention, Intensity Modulated Radiotherapy (IMRT) to Ipsilateral Neck - Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 90 | 2025-01-01 | 2024-09-03 |
| A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07 - HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Theravectys S.A. | 72 | 2024-08-08 | 2026-02-02 |
| A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors TSC-204-A0201, TSC-204-C0702, TSC-200-A0201 - Head and Neck Cancer, Cervical Cancer | Phase 1 | Active not recruiting | TScan Therapeutics, Inc. | 840 | 2024-05-06 | 2025-11-17 |
| Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) Experimental Observation, Observation per Standard of Care, Adjuvant Treatment per Standard of Care - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Maryland, Baltimore | 61 | 2024-03-07 | 2025-11-10 |
| Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma VB10.16, Pembrolizumab - HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC | Phase 1 / Phase 2 | Recruiting | Nykode Therapeutics ASA | 110 | 2023-12-19 | 2026-08-26 |
| A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC) NavDx - Oropharyngeal Cancer, HPV-Related Carcinoma | Active not recruiting | Memorial Sloan Kettering Cancer Center | 9 | 2023-03-31 | 2026-09-23 | |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers E7 TCR-T cells, Aldesleukin - Cervical Cancer, Throat Cancer | Phase 2 | Recruiting | Christian Hinrichs | 20 | 2023-03-07 | 2026-10-28 |
| The SPOT-HPV Study Salivary TTMV-HPV DNA Test, Blood TTMV-HPV DNA Test - HPV Infection, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Completed | Dana-Farber Cancer Institute | 360 | 2022-11-30 | 2026-01-21 | |
| De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx Intensity-Modulated Radiation Therapy (IMRT) - HPV Positive Oropharyngeal Squamous Cell Carcinoma | Recruiting | University of California, Irvine | 111 | 2022-11-03 | 2026-05-05 | |
| TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers HB-201, HB-202, Carboplatin - Human Papilloma Virus, HPV | Phase 1 / Phase 2 | Active not recruiting | University of Chicago | 35 | 2022-08-22 | 2026-04-24 |
Showing 20 of 39. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (17) · Oropharyngeal Neoplasms (14) · Head and Neck Neoplasms (12) · Carcinoma, Squamous Cell (5) · Papillomavirus Infections (5) · Uterine Cervical Neoplasms (5) · Melanoma (3) · Neoplasm Metastasis (3) · Anus Neoplasms (2) · Hypopharyngeal Neoplasms (2) · Laryngeal Neoplasms (2) · Penile Neoplasms (2) · Vaginal Neoplasms (2) · Vulvar Neoplasms (2) · Carcinoma (1)
Neoplasms (33) · Neoplasms by Site (31) · Neoplasms by Histologic Type (22) · Neoplasms, Glandular and Epithelial (20) · Carcinoma (19) · Head and Neck Neoplasms (19) · Otorhinolaryngologic Diseases (15) · Otorhinolaryngologic Neoplasms (15) · Pharyngeal Diseases (15) · Pharyngeal Neoplasms (15) · Stomatognathic Diseases (15) · Carcinoma, Squamous Cell (13) · Genital Diseases (10) · Pathological Conditions, Signs and Symptoms (10) · Urogenital Diseases (10)
Cisplatin (6) · Radiotherapy, Intensity-Modulated (6) · pembrolizumab (6) · Adoptive Transfer (2) · Carboplatin (2) · Cetuximab (2) · Paclitaxel (2) · Radiotherapy (2) · aldesleukin (2) · Alpelisib (1) · Chemoradiotherapy (1) · Costs and Cost Analysis (1) · Hematologic Tests (1) · MEDI0457 (1) · Magnetic Resonance Spectroscopy (1)
Memorial Sloan Kettering Cancer Center (3) · Abramson Cancer Center at Penn Medicine (2) · Christian Hinrichs (2) · Dana-Farber Cancer Institute (2) · PDS Biotechnology Corp. (2) · University of Maryland, Baltimore (2) · Andrew Sikora (1) · Brigham and Women's Hospital (1) · Cedars-Sinai Medical Center (1) · Cellid Co., Ltd. (1) · Cue Biopharma (1) · Indiana University (1) · Jonathan Schoenfeld, MD, MPH (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Massachusetts Eye and Ear Infirmary (1)
United States (30) · Australia (3) · Canada (2) · Puerto Rico (2) · South Korea (2) · United Kingdom (2) · Brazil (1) · France (1) · Germany (1) · Hungary (1) · Ireland (1) · Mexico (1) · New Zealand (1) · Norway (1) · Poland (1)
Christian S Hinrichs, MD (2) · Acharf Shamseddine, MD (1) · Adrian I Mendez, MD (1) · Andrew G Sikora, MD PhD (1) · Anna Lawless (1) · Ari Rosenberg, MD (1) · Brett Miles, MD (1) · Carole Fakhry, MD, MPH (1) · D Rischin, Dr (1) · David Spriggs, MD (1) · David T Schaaf, MD (1) · Dawn Pinchasik, MD (1) · Eleni M Rettig, MD (1) · Eric Chen, MD (1) · Eric Miller, MD, PhD (1)
PMID 31964784, PMID 33004905, PMID 34098030, PMID 40609265, PMID 42098120, PMID 42752531
P30CA016058 (1), P30CA023074 (1), R03DE030550 (1), U01CA287904 (1), U54CA242639 (1)